Cas:237424-17-8 2,3-Difluoro-4-(trifluoromethyl)benzoic acid manufacturer & supplier

We serve Chemical Name:2,3-Difluoro-4-(trifluoromethyl)benzoic acid CAS:237424-17-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2,3-Difluoro-4-(trifluoromethyl)benzoic acid

Chemical Name:2,3-Difluoro-4-(trifluoromethyl)benzoic acid
CAS.NO:237424-17-8
Synonyms:RARECHEM AL BO 0850;4-Carboxy-2,3-difluorobenzotrifluoride;2,3-difluoro-4-trifluoromethyl-benzoic acid;2,3,7,8-TCDF
Molecular Formula:C8H3F5O2
Molecular Weight:226.10000
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:241.4ºC at 760mmHg
Density:1.571g/cm3
Index of Refraction:1.443
PSA:37.30000
Exact Mass:226.00500
LogP:2.68180

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like RARECHEM AL BO 0850 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,3,7,8-TCDF physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3-difluoro-4-trifluoromethyl-benzoic acid Use and application,4-Carboxy-2,3-difluorobenzotrifluoride technical grade,usp/ep/jp grade.


Related News: J.P. Morgan and William Blair analysts still backed iRhythm for the long-term despite its recent challenges. William Blair analysts wrote that the company is still a leader of a cardiac monitoring market that is under 20% penetrated and valued at approximately $2 billion. (5-ethoxy-3-chloro-pent-2-enyl)-diethyl-amine manufacturers “We were all surprised by the speed at which the oncology market grew in China,” Dunoyer said on the call. “Even if we don’t expect rare disease to grow at the same speed, it is likely that the speed at which the rare disease grows in China is going to be faster than other markets of the world.” 3-(2-Bromo-6-isopropylphenoxy)-6-chloro-4-pyridazinol suppliers In addition, AstraZeneca is exploring the potential of anifrolumab in a variety of diseases where type I interferon plays a key role, including lupus nephritis, cutaneous lupus erythematosus and myositis. (15α,13E)-9-oxo-15-hydroxy-16-(3-(2-fluorophenyl)phenyl)-17,18,19,20-tetranor-8-azaprost-13-enoic acid vendor & factory.